Amrutanjan Health Care Ltd
Amrutanjan Health Care Q3 FY24 earnings call: Revenue & Margins
Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹117Cr
- Net profit
- ₹17Cr
- Margin
- 18%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
Revenue & Sales Performance
- Q3 FY24 net sales:
- OTC: Rs. 111.79 Cr (up 19.55% YoY)
- Beverages: Rs. 5.18 Cr (up 41.92% YoY)
- Comfy: Rs. 30.18 Cr (up 67.11% YoY)
- Electro Plus: Rs. 4.86 Cr (up 59.87% YoY)
- Total Net Sales: Rs. 116.99 Cr (up 19.81% YoY)
- Q3 FY24 profit:
- Profit Before Tax: Rs. 23.71 Cr (up 63.52%)
- Profit After Tax: Rs. 17.45 Cr (up 62.93%)
- Volume outlook:
- Balm SKU 8ml grew double digits in Q3; cautiously optimistic about sustaining growth.
- Comfy sales grew 67.11% in Q3; projected to cross Rs. 100 Cr (INR 1 Billion) revenue annually.
- Growth expected in large packs of Comfy pads as consumers trade up.
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q3 FY24 results — key figures
| ₹ Cr | Q3 FY24 | Q2 FY24 | QoQ |
|---|---|---|---|
| Revenue | 117 | 99 | +18.2% |
| Operating profit (EBITDA) | 22 | 7 | +214.3% |
| Operating margin | 18% | 7% | +11 pp |
| Profit before tax | 24 | 9 | +166.7% |
| Net profit (PAT) | 17 | 7 | +142.9% |
| EPS (₹) | 6.04 | 2.37 | +154.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key concall takeaways from Wockhardt Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3…
- Anuh Pharma (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…
- Bharat Parenterals (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key concall takeaways from Bharat Parenterals Ltd's Q3 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.